Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol

Objective: This study aimed to determine the effect of calcitriol on serum concentrations of fibroblast growth factor-23 (FGF-23), sclerostin, intact parathyroid hormone (PTH), and handgrip strength in postmenopausal women with low bone mass.

Methods: A randomized, double-blind controlled trial was carried out among 141 postmenopausal women with low bone mass. Participants were randomized into two groups: 75 participants received calcitriol 0.5 μg/day and 66 participants received a placebo for 12 weeks.

Results: After 12-week calcitriol treatment, significant decreases in serum intact PTH (P = 0.035) and sclerostin (P = 0.039), as well as significant increases in serum creatinine (P = 0.027), uric acid (P = 0.032), 24-hour urinary calcium (P = 0.0026), and left handgrip strength (P = 0.03), were observed, compared to placebo group. Level of serum sclerostin was weakly but significantly positively correlated with serum PTH (r = 0.277; P = 0.01) and negatively correlated with 24-hour urinary calcium (r = −0.221; P = 0.04) and left handgrip strength (r = −0.338; P = 0.03) after calcitriol treatment. Multiple regression analysis demonstrated that decrease in serum sclerostin was associated with decrease in PTH serum level after calcitriol treatment (OR, 7.90; 95% CI, 2.28–27.42; P = 0.035).

Conclusion: Calcitriol treatment yields a considerable decrease in serum sclerostin and significant increase of handgrip strength, and the change in serum sclerostin is regulated by serum PTH and by muscle strength.

Keywords: calcitriol, FGF-23, fibroblast growth factor 23, handgrip, intact PTH, sclerostin

Introduction

Osteoporosis is a disease that affects primarily postmenopausal women, especially those with vitamin D deficiency and a lifestyle of low physical activity. In China, the prevalence of osteoporosis has grown rapidly, the prevalence of osteoporosis in people aged 50 years and older in 2015 being more than twice the prevalence identified in 2006 (34.65% vs 15.7%, respectively). The prevalence was higher in females than in males (25.41% vs 15.33%, respectively) and increased with age. Moreover, vitamin D deficiency is also very common in China. In our previous study, more than 82.5% of elderly community residents had vitamin D insufficiency, and approximately 43% had vitamin D deficiency—even during summer. Deficiency of vitamin D inevitably leads to secondary hyperparathyroidism, which augments bone resorption, compromises bone quality, and increases risk of falling and fractures.

Sclerostin is an osteocyte-secreted glycoprotein that inhibits osteoblast proliferation and differentiation, as well as promoting apoptosis by inhibiting canonical
Wnt-signaling. Sclerostin may help modulate systemic and local factors, such as calcitriol, parathyroid hormone (PTH), glucocorticoids, and tumor necrosis factor (TNF)-alpha. We determined that serum sclerostin also positively correlates with bone mineral density (BMD), negatively correlates with serum TGF-beta, and changes with age in the postmenopausal period. Fibroblast growth factor-23 (FGF-23) is a bone-derived hormone that regulates homeostasis of phosphate and 1,25-dihydroxyvitamin D (1,25(OH)_2D). As the most metabolically active form of vitamin D, 1,25(OH)_2D plays a key role in the regulation of extracellular calcium concentration and bone metabolism. Calcitriol has been used widely to treat osteoporosis, especially in the elderly population in China. However, the effects of calcitriol on the levels of serum FGF-23 and sclerostin have not been determined; moreover, it remains unclear whether there are correlations among FGF-23, sclerostin, and calcitriol. In the current study, we assessed the effect of calcitriol on serum FGF-23 and sclerostin in postmenopausal women with low bone mass to ascertain the following: 1) whether serum FGF-23 and sclerostin significantly changed after calcitriol treatment; 2) whether these changes evoke corresponding changes in serum intact PTH (iPTH) and bone turnover; and 3) the changes in muscle mass and muscle strength during treatment.

Methods

Study design and study population

We carried out a randomized, double-blind controlled study. The logistics of calcitriol and placebo, along with each code for randomization, were prepared by personnel from the Department of Medicine, Qingdao Chia Tai Haier Pharmaceutical Co, Ltd, Qingdao, Shandong, China. Both investigators and participants were unaware of the codes.

All the participants were recruited from the town of Meilong in Minhang District of Shanghai, China, from November 2016 to April 2017. Totally, 320 postmenopausal women were recruited, and after excluding patients who did not give consent (58 patients), who had normal bone mass (44 patients), who had a level of serum 25(OH)D that exceeded 30 ng/mL (45 patients), and who did not comply with or finish the study (32 patients), 141 participants completed the study and were included in the analysis. Based on a review of medical charts and physical examination, we selected participants in good health. All were able to walk independently. No included patient had severe disease that interfered with vitamin D metabolism, such as hyperthyroidism, hyperparathyroidism, hepatic failure, renal failure, or end-stage cancer. No included patient received medication that was likely to affect bone or vitamin D metabolism (eg, glucocorticoids, heparin, warfarin, thyroxine, sex hormones, bisphosphonates, selective estrogen-receptor modulators, calcitonin, PTH analogs, or calcitriol). This study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. Approval was obtained from the Huadong Hospital Ethics Committee, Shanghai, China (project number 2014K004).

Treatment

Participants were randomized to receive either calcitriol or placebo. The calcitriol group received oral calcitriol (Qingdao Chia Tai Haier Pharmaceutical Co, Ltd) at a dosage of 0.5 µg/day for 12 weeks. All the participants were required to avoid calcium supplements and were asked to maintain their usual dietary habits during the study period. According to a survey launched in 2015 in China, the average calcium intake from the food for old persons was about 400 mg/day; so, dietary calcium intake was lacking in China.

Anthropometry

All anthropometric measurements were made by well-trained staff. Weight and height were determined with the participants dressed in light clothing and without wearing shoes. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters (kg/m²).

Handgrip measurement

Isometric handgrip was measured using a digital handgrip dynamometer (Takei Scientific Instruments, Niigata, Japan). Grip strength was measured three times per hand with the patient standing. The results were represented as the combined grip strength in kilograms, ie, the sum of the largest reading from each hand.

Laboratory analyses

Patients underwent collection of fasting serum samples for biochemical analysis, including bone turnover markers, calcitriotropic hormones, FGF-23, and sclerostin. These factors were analyzed at baseline and at the end of the study. Serum samples were collected between 0700 and 0900 hours after a 10-hour fast.

Bone density measurements

BMD values, including those for lumbar vertebrae (L1–4), left femoral neck (FN), and total hip, were measured using
dual-energy X-ray absorptiometry (DXA; Hologic Delphi A; Hologic Inc, Waltham, MA, USA). Body composition was measured by a whole body scan with the same machine operated in the slow scan mode. To minimize interobserver variations, all scans and analyses were conducted by the same investigator. The day-to-day coefficients of variance (CVs) of these observations were 0.86% in the lumbar spine BMD, 1.86% in the femur BMD, 0.95% in the total hip BMD, and 0.74% in lean mass. The densitometer was standardized using a standard phantom prior to each measurement.

### Analysis of serum FGF-23 and sclerostin levels

Commercially available ELISA kits for FGF-23 (Kainos Laboratories Inc, Tokyo, Japan; intraassay and interassay CV, <2.8% and <3.8%, respectively) and sclerostin (R&D Systems, Minneapolis, MN, USA; intraassay and interassay CV, <2.1% and <10.8%, respectively) were applied for measurement of serum FGF-23 and sclerostin.

### Bone turnover markers

Serum osteocalcin (bone Gla protein [BGP]; Hoffman-La Roche Ltd., Basel, Switzerland) and serum cross-linked C-terminal telopeptide of type I collagen (CTX; Roche) were used as bone turnover markers. The within-run and between-run intra-assay CV was <7% for osteocalcin and <6% for CTX.

### Calcitropic hormone measurements

Serum iPTH and 25(OH)D were measured by electrochemiluminescence (Roche). The within-run intra-assay CV was <3.4%, and the between-run intra-assay CV was <7%.

### Statistical analyses

Data were represented as mean±SD, mean (95% CI), and median (IQR) as appropriate. Variables were compared with the independent-samples Student’s t-test if normally distributed or with the Mann–Whitney U test if the distribution was skewed. Paired Student’s t-test and Wilcoxon signed-rank test were used for within-group comparisons before and after treatment. Pearson or Spearman correlation coefficients were determined to assess associations of serum sclerostin or FGF-23 with bone turnover markers, calcitropic hormones, and biochemical markers. Absolute changes in plasma FGF-23, sclerostin, iPTH, 25(OH)D, calcium, phosphorus, ALP, uric acid, creatinine, bone turnover markers, 24-hour urinary calcium concentrations, and handgrip strengths from baseline to Week 12 were ascertained in the calcitriol treatment group. These parameters were stratified by the direction of the change from baseline to Week 12: decrease (Week 12 – baseline ≤0) or increase (Week 12 – baseline >0). Logistic regression modeling was performed to estimate the association of the decrease/increase in each analyte with the decrease/increase in sclerostin or FGF-23. All analyses were performed using SPSS 16.0 (IBM Corporation, Armonk, NY, USA). Two-tailed P-values <0.05 were considered statistically significant.

### Results

Demographic information and baseline characteristics of the study subjects are shown in Table 1. There was no statistically significant difference for all the characteristics between the two groups. The BMD values of all participants were indicative of osteopenia or osteoporosis. Appendicular skeletal muscle mass index (ASMI = appendicular skeletal muscle mass/height2) was 6.23±0.73 kg/m2 or 5.95±0.69 kg/m2, respectively, which showed that these postmenopausal women did not suffer from sarcopenia according to the cut point value of our previous study.8 Blood levels of iPTH were 44.78±15.5 pg/mL and 47.0±21.1 pg/mL, respectively, and those of 25(OH)D were 17.10±7.8 ng/mL and 15.8±9.6 ng/mL, respectively. Blood levels of sclerostin were 103.4±28.0 pg/mL and 120.55±52.6 pg/mL, respectively, and for FGF-23, the levels were 101.7±46.0 ng/mL and 118.79±24.7 ng/mL, respectively, which did not show any significant difference between the two groups (Table 1).

In the calcitriol treatment group, serum iPTH, sclerostin, ALP, serum creatinine, uric acid, serum glucose, and 24-hour urinary calcium levels were found to be significantly changed posttreatment (Table 1). No significant change in serum levels of 25(OH)D, FGF-23, calcium, or phosphorus were noted. Left handgrip strength increased significantly by 3.7% (P=0.019), but right handgrip strength did not change significantly. However, in the placebo group, there was no significant change for all the parameters between pretreatment and posttreatment values (Table 2). Treatment with calcitriol for 12 weeks resulted in a significant increase in serum uric acid and creatinine, but all of these parameters remained within the normal range from the pretreatment to the posttreatment periods (Table 2).

As for the difference between the calcitriol and placebo groups after 12-week treatment, significant decreases in serum iPTH (mean change: −8.08 pg/mL, 95% CI: −10.55 to −5.38 pg/mL; P=0.035) and sclerostin (mean change: −7.05 pg/mL, 95% CI: −19.8 to −2.75 pg/mL; P=0.039),
as well as significant increases in serum creatinine (mean change: 2.00 mmol/L, 95% CI: 1.08 to 3.09 mmol/L; \( P = 0.027 \)), uric acid (mean change: 7.89 mmol/L, 95% CI: 2.2 to 13.99 mmol/L; \( P = 0.032 \)), 24-hour urinary calcium (mean change: 2.78 mmol, 95% CI: 1.10 to 3.05 mmol; \( P = 0.0026 \)), and left handgrip strength (mean change: 2.12 kg, 95% CI: 1.87 to 2.36 kg; \( P = 0.03 \)) were observed, compared to the placebo group (Table 2).

Results of pretreatment and posttreatment correlation analyses of sclerostin and FGF-23 with bone metabolic markers and other parameters of calcitriol treatment group are summarized in Table 3. At baseline, sclerostin and FGF-23 were not correlated with 25(OH)\(_2\)D, iPTH, bone turnover markers, or other parameters. In contrast, posttreatment serum sclerostin level was weakly but significantly positively correlated with iPTH level \( (r = 0.277; P = 0.01) \) and negatively correlated with left handgrip strength \( (r = -0.338; P = 0.03) \) and 24-hour urinary calcium level \( (r = -0.221; P = 0.04) \). Posttreatment serum FGF-23 level was negatively correlated with CTX \( (r = -0.326; P = 0.02) \) and 24-hour urinary calcium \( (r = -0.356; P = 0.01) \) levels (Table 3). We noted that urinary calcium was also negatively correlated with posttreatment iPTH level \( (r = -0.335; P = 0.001) \); we further determined that, after adjusting for urinary calcium level, serum sclerostin was still positively correlated with iPTH \( (r = 0.218; P = 0.043) \) and negatively correlated with left handgrip strength \( (r = -0.317; P = 0.041) \).

Factors associated with a decrease in the serum sclerostin or FGF-23 level of the calcitriol treatment group are presented in Table 4. We constructed a multivariate logistic regression model to examine the relationship between any change in the parameters and the desired end point of a significant decrease in serum sclerostin level. We found that a decrease in serum iPTH was associated with a significant decrease in serum sclerostin after treatment with calcitriol (OR, 7.90; 95% CI, 2.28–27.42; \( P = 0.002 \); Table 4).
Table 2 Changes in biochemical parameters and markers of bone turnover between baseline and 12 weeks

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=66)</th>
<th></th>
<th>P-value</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean change (95% CI)</td>
<td>P-value</td>
<td>Mean change (95% CI)</td>
<td>P-value</td>
<td>Between-group difference (compared to placebo group)</td>
<td>P-value</td>
</tr>
<tr>
<td>BMI</td>
<td>−0.30 (−1.46 to 0.87)</td>
<td>0.61</td>
<td>0.32 (−0.88 to 1.52)</td>
<td>0.60</td>
<td>1.84 (0.65 to 3.23)</td>
<td>0.33</td>
</tr>
<tr>
<td>Grip strength (left), kg</td>
<td>−0.87 (−2.42 to 0.66)</td>
<td>0.384</td>
<td>2.96 (1.29 to 3.04)</td>
<td>0.019</td>
<td>2.12 (1.87 to 2.36)</td>
<td>0.03</td>
</tr>
<tr>
<td>Grip strength (right), kg</td>
<td>−0.255 (−0.13 to 0.328)</td>
<td>0.799</td>
<td>1.953 (−0.044 to 2.025)</td>
<td>0.051</td>
<td>1.81 (−0.71 to 1.99)</td>
<td>0.07</td>
</tr>
<tr>
<td>ASMI, kg/m²</td>
<td>0.02 (−0.02 to 0.26)</td>
<td>0.86</td>
<td>−0.06 (−1.32 to 0.37)</td>
<td>0.62</td>
<td>0.56 (−0.27 to 0.84)</td>
<td>0.23</td>
</tr>
<tr>
<td>FGF-23, pg/mL</td>
<td>−5.92 (−11.99 to 13.83)</td>
<td>0.14</td>
<td>−6.77 (−27.3 to 13.79)</td>
<td>0.51</td>
<td>−8.36 (−12.21 to 25.77)</td>
<td>0.65</td>
</tr>
<tr>
<td>SOST, pg/mL</td>
<td>0.19 (−0.42 to 0.81)</td>
<td>0.53</td>
<td>−5.91 (−22.0 to −3.75)</td>
<td>0.016</td>
<td>−7.05 (−19.8 to −2.75)</td>
<td>0.039</td>
</tr>
<tr>
<td>PTH, pg/mL</td>
<td>5.49 (−5.01 to 15.99)</td>
<td>0.29</td>
<td>−7.79 (−11.13 to −4.44)</td>
<td>0.000</td>
<td>−8.08 (−10.55 to −5.38)</td>
<td>0.035</td>
</tr>
<tr>
<td>25(OH)D, ng/mL</td>
<td>0.10 (−3.16 to 3.36)</td>
<td>0.95</td>
<td>−1.89 (−3.17 to 0.60)</td>
<td>0.25</td>
<td>5.25 (−2.37 to 8.14)</td>
<td>0.68</td>
</tr>
<tr>
<td>CTX, pg/mL</td>
<td>−18.39 (−98.56 to 61.77)</td>
<td>0.64</td>
<td>18.31 (−14.82 to 51.44)</td>
<td>0.27</td>
<td>−19.98 (−95.05 to 55.04)</td>
<td>0.596</td>
</tr>
<tr>
<td>BGP, ng/mL</td>
<td>3.74 (−0.37 to 7.87)</td>
<td>0.07</td>
<td>−0.47 (0.27 to −1.25)</td>
<td>0.21</td>
<td>−1.94 (−4.38 to 0.50)</td>
<td>0.117</td>
</tr>
<tr>
<td>ALP, IU/L</td>
<td>−4.27 (−5.24 to 1.29)</td>
<td>0.21</td>
<td>−7.03 (−10.25 to −3.81)</td>
<td>0.03</td>
<td>−5.17 (−12.87 to 2.54)</td>
<td>0.45</td>
</tr>
<tr>
<td>Blood glucose, mmol/L</td>
<td>0.05 (−0.85 to 0.94)</td>
<td>0.09</td>
<td>−0.35 (−0.53 to −0.17)</td>
<td>0.045</td>
<td>0.01 (−0.61 to 0.87)</td>
<td>0.727</td>
</tr>
<tr>
<td>UA, mmol/L</td>
<td>−27.98 (−81.5 to 25.53)</td>
<td>0.29</td>
<td>20.23 (8.91 to 31.53)</td>
<td>0.001</td>
<td>7.89 (2.23 to 13.99)</td>
<td>0.032</td>
</tr>
<tr>
<td>Serum Cr, mmol/L</td>
<td>2.03 (−4.07 to 8.12)</td>
<td>0.59</td>
<td>3.92 (2.41 to 5.42)</td>
<td>0.004</td>
<td>2.00 (1.08 to 3.09)</td>
<td>0.027</td>
</tr>
<tr>
<td>TC, mmol/L</td>
<td>4.85 (−6.87 to 16.57)</td>
<td>0.38</td>
<td>0.10 (−0.90 to 0.30)</td>
<td>0.298</td>
<td>−0.40 (−0.89 to 0.08)</td>
<td>0.101</td>
</tr>
<tr>
<td>TG, mmol/L</td>
<td>17.27 (−20.39 to 54.95)</td>
<td>0.33</td>
<td>−0.19 (−0.33 to 0.05)</td>
<td>0.07</td>
<td>0.48 (−0.02 to 0.94)</td>
<td>0.061</td>
</tr>
<tr>
<td>Serum Ca, mmol/L</td>
<td>−0.04 (−0.08 to 0.015)</td>
<td>0.16</td>
<td>0.02 (−0.03 to 0.04)</td>
<td>0.09</td>
<td>−0.03 (−0.65 to 0.01)</td>
<td>0.064</td>
</tr>
<tr>
<td>Serum P, mmol/L</td>
<td>0.91 (−0.93 to 2.75)</td>
<td>0.32</td>
<td>0.05 (−0.01 to 0.08)</td>
<td>0.11</td>
<td>−0.08 (−0.14 to 0.02)</td>
<td>0.36</td>
</tr>
<tr>
<td>Urinary Ca, mmol/L</td>
<td>1.92 (−1.99 to 13.83)</td>
<td>0.15</td>
<td>1.51 (0.83 to 2.19)</td>
<td>0.000</td>
<td>2.78 (1.10 to 3.45)</td>
<td>0.026</td>
</tr>
</tbody>
</table>

Note: Data are presented as mean change and 95% CI. Abbreviations: 25(OH)D, serum 25-hydroxyvitamin D; ASMI, appendicular skeletal mass index; BGP, bone gla protein or osteocalcin; BMI, body mass index; BMD, bone mineral density; BMD (1–4), BMD of lumbar vertebrae 1–4; BMD (FN), BMD of femur neck; BMD (TH), BMD of total hip; BMI, body mass index; Cr, creatinine; CTX, cross-linked C-terminal telopeptide of type I collagen; FGF-23, fibroblast growth factor-23; GFR, glomerular filtration rate; Grip (left), grip strength of left hand; Grip (right), grip strength of right hand; PTH, parathyroid hormone; SOST, sclerostin; TC, total cholesterol; TG, triglyceride; UA, uric acid; Urinary Ca, 24-hour urinary calcium.

Discussion
Both sclerostin and FGF-23 are produced in osteocytes, and they function as crucial calcium regulators in bone mineralization balance. Sclerostin and FGF-23 are known to inhibit bone formation, with several cross-sectional studies having identified inverse associations of serum FGF-23 and sclerostin with numerous biochemical markers of bone turnover. In this study, we found that calcitriol treatment yielded significant increases in serum iPTH and sclerostin, as well as significant increases in serum creatinine, uric acid, and left handgrip strength. Thus, serum sclerostin was negatively regulated by calcitriol, and the change of sclerostin positively correlated with the change of iPTH.

Several studies have addressed the putative regulation of vitamin D by sclerostin, but no study has identified the reason and mechanism for this phenomenon. Sandal et al14 found that pregnant women with vitamin D deficiency had circulating sclerostin levels that were similar to those who were vitamin D sufficient. In a study that included 279 men and women, calcium and vitamin D supplementation at a dosage of 700 IU/day for 2 years increased serum sclerostin levels in men (13.1% increase; P<0.01 vs placebo) but did not change sclerostin levels significantly in women.12 Sankaralingam et al13 reported that intramuscular injection of a 300,000 IU bolus of vitamin D significantly increased the concentration of serum sclerostin. Acibucu et al14 evaluated a group of 44 patients with vitamin D deficiency who had a significant decrease (−19.4%; P<0.01) in sclerostin levels after being treated with monthly intramuscular injection of 300,000 IU of vitamin D (cholecalciferol). Cidem et al15 demonstrated that treatment of vitamin D–deficient patients with calcium at a dosage of 1,200 mg/day for 2 months and vitamin D3 at a dosage of 300,000 IU/week for 1 month produced significantly increased serum 25(OH)D and significantly decreased serum sclerostin in these patients. In this study, we found that treatment using calcitriol 0.5 µg/day without calcium in postmenopausal women for only 12 weeks significantly increased muscle strength and depressed serum level of iPTH and sclerostin.

Active vitamin D can augment muscle strength and improve lower limb balance. The results of multiple studies have shown that postmenopausal women who take active vitamin D have increased muscle power, show a longer walking distance, and are more likely to have a normal PTH
Table 3  Correlation analyses between sclerostin, FGF-23, and other parameters before and after treatment in the calcitriol group

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>PTH</th>
<th>25(OH)D</th>
<th>CTX</th>
<th>ALP</th>
<th>Cr</th>
<th>UA</th>
<th>Serum Ca</th>
<th>Serum P</th>
<th>Urinary Ca</th>
<th>Grip strength (left)</th>
<th>Grip strength (right)</th>
<th>SOST</th>
<th>FGF-23</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOST</td>
<td>0.13810</td>
<td>0.10234</td>
<td>-0.08046</td>
<td>-0.13431</td>
<td>0.047067</td>
<td>0.232032</td>
<td>0.020925</td>
<td>0.00596</td>
<td>-0.00398</td>
<td>-0.14318</td>
<td>0.09355</td>
<td>-0.071045</td>
<td>1</td>
</tr>
<tr>
<td>FGF-23</td>
<td>0.17710</td>
<td>0.09140</td>
<td>-0.018209</td>
<td>-0.118308</td>
<td>0.083044</td>
<td>0.232032</td>
<td>0.020925</td>
<td>0.00596</td>
<td>-0.00398</td>
<td>-0.14318</td>
<td>0.09355</td>
<td>-0.071045</td>
<td>1</td>
</tr>
<tr>
<td>Posttreatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOST</td>
<td>0.27701</td>
<td>-0.057640</td>
<td>0.069533</td>
<td>-0.131032</td>
<td>-0.006196</td>
<td>-0.010433</td>
<td>-0.09637</td>
<td>-0.06734</td>
<td>-0.22104</td>
<td>-0.338083</td>
<td>-0.291056</td>
<td>1</td>
<td>0.045068</td>
</tr>
<tr>
<td>FGF-23</td>
<td>0.015089</td>
<td>-0.128204</td>
<td>-0.326041</td>
<td>0.082045</td>
<td>0.018037</td>
<td>0.109311</td>
<td>0.027045</td>
<td>0.165153</td>
<td>-0.356041</td>
<td>-0.036082</td>
<td>-0.111047</td>
<td>1</td>
<td>0.045068</td>
</tr>
</tbody>
</table>

Note: Bold figures indicate statistically significant.

Abbreviations: 25(OH)D, serum 1,25-dihydroxyvitamin D; Ca, serum calcium; Cr, creatinine; CTX, cross-linked C-terminal telopeptide of type I collagen; FGF-23, fibroblast growth factor-23; Grip (left), grip strength of left hand; Grip (right), grip strength of right hand; PTH, parathyroid hormone; SOST, sclerostin; UA, uric acid; Urinary Ca, 24-hour urinary calcium.
Table 4 Results of multiple regression for the decrease in sclerostin or FGF-23 posttreatment in the calcitriol group

<table>
<thead>
<tr>
<th>SOST</th>
<th>PTH</th>
<th>UA</th>
<th>Cr</th>
<th>ALP</th>
<th>Urinary Ca</th>
<th>Grip strength (left)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B OR (95% CI) for decrease in SOST</td>
<td>2.07</td>
<td>1.75</td>
<td>1.18</td>
<td>1.83</td>
<td>0.96</td>
<td>0.54</td>
</tr>
<tr>
<td>P-value</td>
<td>7.90 (2.28–27.42)</td>
<td>0.001</td>
<td>0.13</td>
<td>0.17</td>
<td>0.17</td>
<td>0.33</td>
</tr>
<tr>
<td>B OR (95% CI) for decrease in FGF-23</td>
<td>-0.03</td>
<td>-0.13</td>
<td>-0.35</td>
<td>0.13</td>
<td>-5.16</td>
<td>0.13</td>
</tr>
</tbody>
</table>

Notes: Decreases in FGF-23 are defined as having change from baseline ≤0. Decreases in SOST are defined as having change from baseline ≥0.

Abbreviations: Cr, creatinine; FGF-23, fibroblast growth factor-23; Grip (left), grip strength of left hand; PTH, parathyroid hormone; SOST, sclerostin; UA, serum uric acid; Urinary Ca, 24-hour urinary calcium.

could have favorable effects on skeletal muscle strength in patients who are older. Molino-Lova et al17 showed that high levels of uric acid in serum were independently associated with better muscle function and that uric acid had a favorable effect on progression of sarcopenia among individuals in the oldest age group. Thus, muscle strength and volume correlate with the level of serum creatinine and uric acid in their physiologic range.

However, the effects of calcitriol on serum creatinine and uric acid have not been addressed sufficiently in the literature. In the current study, all the patients were healthy postmenopausal women who maintained their typical dietary habits and lifestyle and were monitored for only 12 weeks. Patients in this study had serum levels of creatinine and uric acid in the normal range pretreatment and posttreatment. Therefore, we speculate that the observed increases in serum creatinine and uric acid after calcitriol treatment can be attributed to improvements in muscle metabolism. So, we cannot rule out the possibility that the increased muscle strength caused by calcitriol treatment modulated the serum levels of sclerostin, creatinine, and uric acid.

Conclusion

Our results show that circulating concentrations of sclerostin and iPTH were decreased and serum creatinine, uric acid, and muscle strength were enhanced in response to treatment with calcitriol for 12 weeks. A significant correlation was seen among serum sclerostin, serum iPTH, and muscle strength posttreatment. These findings raise the possibility that calcitriol may mediate the levels of iPTH and skeletal anabolic metabolism, which, in turn, further suppresses the production of sclerostin. More research is warranted to dissect this putative physiologic mechanism.

Acknowledgments

We thank Xin Jiang, Hongli Shi, Jiemin Gan, and Huimin Zhou for their work on ELISA detection of sclerostin, FGF-23, and some biomarkers in this study, and we also like to thank all participants of the study and the involved laboratory staff. We also give great thanks to BioMed Proofreading LLC for getting this manuscript edited by native English-speaking experts. This study was supported by the National Natural Science Foundation of China (NSFC; grant number 81471089), Natural Science Foundation of Shanghai (16411954600), Shanghai Hospital Development Center (SHDC12016201), and Shanghai Municipal Commission of Health (2013ZYJB0801).

Disclosure

The authors report no conflicts of interest in this work.

References


Clinical Interventions in Aging. 2018;13